Kategorie
Arzneimittel
300 Substanzen · sortierbar nach Meldungen, ROR oder % schwerwiegend.
300 von 300 angezeigt
| Produkt ↓ | Meldungen | % schwerwiegend | Top-Signal | ROR | Typ |
|---|---|---|---|---|---|
zolpidem tartrate — | 132.956 | 69.3% | Vollendeter Suizid | 8.5 | drug |
warfarin — | 126.794 | 79.5% | Erhöhtes International Normalized Ratio (INR) | 100.9 | drug |
vitamin c — | 89.288 | 58.8% | Infusionsbedingte Reaktion | 10.4 | drug |
vitamin — | 120.098 | 59.0% | Infusionsbedingte Reaktion | 8.6 | drug |
venlafaxine hydrochloride — | 129.795 | 74.2% | Serotonin-Syndrom | 24.2 | drug |
venlafaxine — | 129.795 | 74.2% | Serotonin-Syndrom | 24.2 | drug |
vedolizumab — | 83.516 | 86.7% | Verminderte therapeutische Reaktionszeit | 4246.7 | drug |
varenicline tartrate — | 79.359 | 40.7% | Abnorme Träume | 114.1 | drug |
varenicline — | 82.301 | 39.5% | Abnorme Träume | 109.9 | drug |
valsartan — | 242.787 | 65.0% | Niedriger Blutdruck | 7.2 | drug |
valacyclovir hydrochloride — | 68.558 | 69.3% | Zytokinfreisetzungssyndrom | 16.7 | drug |
valacyclovir — | 68.558 | 69.3% | Zytokinfreisetzungssyndrom | 16.7 | drug |
ustekinumab — | 100.563 | 59.1% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 220.1 | drug |
upadacitinib — | 76.996 | 67.2% | Wirbelsäulenoperation | 25.0 | drug |
trimethoprim — | 93.592 | 83.9% | Fieberhafte Neutropenie | 7.5 | drug |
treprostinil — | 121.655 | 57.6% | Schmerzen an der Infusionsstelle | 144.1 | drug |
trastuzumab — | 86.493 | 80.0% | Haarerkrankung | 47.7 | drug |
topiramate — | 97.078 | 65.4% | Epilepsie | 13.4 | drug |
tofacitinib — | 185.980 | 48.6% | Handfehlbildung | 149.2 | drug |
tocilizumab — | 112.048 | 76.6% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 1109.5 | drug |
tirzepatide Mounjaro · Zepbound | 140.435 | 17.1% | Veränderte Reaktion auf die Therapie | 72.8 | drug |
tiotropium bromide — | 150.254 | 50.2% | Falscher Verabreichungsweg des Medikaments | 297.6 | drug |
teriparatide — | 111.637 | 37.1% | Erhöhtes Kalzium im Blut | 58.0 | drug |
tenofovir disoproxil fumarate — | 70.071 | 85.2% | Skelettverletzung | 1758.3 | drug |
tadalafil — | 98.103 | 62.5% | Pulmonale arterielle Hypertonie | 53.3 | drug |
tacrolimus extended-release capsules — | 120.821 | 90.5% | Polyomavirus-assoziierte Nierenerkrankung | 465.4 | drug |
tacrolimus — | 152.389 | 89.9% | Polyomavirus-assoziierte Nierenerkrankung | 498.4 | drug |
sulfasalazine — | 76.996 | 83.7% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 1160.9 | drug |
sulfamethoxazole and trimethoprim — | 82.639 | 83.0% | Pancytopenie | 7.8 | drug |
spironolactone — | 137.410 | 78.5% | Hyperkaliämie | 26.3 | drug |
somatropin Genotropin · Humatrope | 71.462 | 26.0% | Problem bei der Gerätedaten-Ausgabe | 2838.9 | drug |
sodium oxybate — | 65.315 | 49.8% | Kataplexie | 610.3 | drug |
sodium chloride tablets — | 70.392 | 80.6% | Knochenmarkhemmung | 55.5 | drug |
sodium chloride tablet — | 70.388 | 80.6% | Knochenmarkhemmung | 55.5 | drug |
sodium chloride — | 264.849 | 82.0% | Bauchfellentzündung | 19.4 | drug |
sitagliptin — | 93.556 | 65.0% | Unzureichende Kontrolle des Diabetes mellitus | 21.2 | drug |
simvastatin — | 261.343 | 72.2% | Rhabdomyolyse | 13.0 | drug |
sildenafil citrate — | 125.270 | 66.5% | Erektion verstärkt | 434.4 | drug |
sildenafil — | 125.271 | 66.5% | Erektion verstärkt | 434.4 | drug |
sertraline hydrochloride — | 116.450 | 63.7% | Suizidgedanken | 5.7 | drug |
sertraline — | 214.801 | 71.6% | Suizidversuch | 6.0 | drug |
sennosides — | 65.497 | 76.8% | Verstopfung | 6.7 | drug |
semaglutide Ozempic · Wegovy | 82.911 | 53.7% | Beeinträchtigte Magenentleerung | 92.1 | drug |
secukinumab — | 158.767 | 39.8% | Psoriasis-Arthropathie | 47.1 | drug |
salmeterol xinafoate — | 67.121 | 57.8% | Atemwegsobstruktion | 45.0 | drug |
sacubitril and valsartan — | 114.605 | 51.0% | Räuspern | 137.4 | drug |
ruxolitinib — | 69.262 | 48.6% | Myelofibrose | 133.2 | drug |
rosuvastatin — | 223.851 | 68.3% | Rhabdomyolyse | 10.3 | drug |
rivaroxaban — | 205.037 | 83.9% | Innere Blutung | 48.6 | drug |
rituximab — | 215.364 | 88.7% | Pemphigus | 325.9 | drug |
ritonavir — | 94.062 | 49.6% | Wiederauftreten der Krankheit | 208.7 | drug |
risperidone — | 131.271 | 66.3% | Gynäkomastie | 755.0 | drug |
risankizumab-rzaa — | 76.587 | 65.2% | Schuppenflechte | 18.5 | drug |
ranitidine — | 230.503 | 93.3% | Darmkrebs | 73.6 | drug |
ramipril — | 121.234 | 93.4% | Pemphigus | 47.4 | drug |
quetiapine — | 188.609 | 78.9% | Diabetes mellitus Typ 2 | 23.9 | drug |
propranolol hydrochloride — | 69.636 | 70.4% | Bradykardie | 8.3 | drug |
pregabalin — | 267.198 | 66.6% | Entzugssyndrom | 9.2 | drug |
prednisone — | 491.157 | 78.5% | Systemischer Lupus erythematodes | 20.1 | drug |
prednisolone oral solution — | 176.279 | 95.5% | Cytomegalievirus-Infektion | 21.6 | drug |
prednisolone oral — | 176.280 | 95.5% | Cytomegalievirus-Infektion | 21.6 | drug |
prednisolone — | 188.016 | 93.2% | Cytomegalievirus-Infektion | 20.7 | drug |
potassium chloride, dextrose monohydrate — | 90.248 | 75.0% | Kaliummangel im Blut | 10.5 | drug |
potassium chloride oral — | 90.239 | 75.1% | Kaliummangel im Blut | 10.5 | drug |
potassium chloride extended-release — | 90.282 | 75.0% | Kaliummangel im Blut | 10.5 | drug |
potassium chloride — | 118.686 | 72.2% | Kaliummangel im Blut | 9.1 | drug |
pomalidomide — | 100.554 | 61.3% | Plasmozytom | 57.4 | drug |
polyethylene glycol 3350 — | 98.501 | 41.6% | Falsche Anwendungsdauer des Produkts | 28.2 | drug |
polyethylene glycol — | 123.342 | 47.0% | Falsche Anwendungsdauer des Produkts | 22.5 | drug |
phenylephrine hydrochloride — | 165.690 | 59.0% | Infusionsbedingte Reaktion | 11.9 | drug |
phenylephrine — | 217.644 | 56.7% | Infusionsbedingte Reaktion | 9.2 | drug |
pembrolizumab — | 100.432 | 87.3% | Nebenniereninsuffizienz | 31.7 | drug |
pegfilgrastim — | 99.745 | 29.5% | Problem mit Gerätehaftung | 847.8 | drug |
paroxetine hydrochloride — | 89.618 | 68.6% | Medikamenteneinnahme während der Schwangerschaft | 24.2 | drug |
paroxetine — | 90.328 | 68.2% | Medikamenteneinnahme während der Schwangerschaft | 24.0 | drug |
pantoprazole sodium — | 144.620 | 78.0% | Nierenversagen im Endstadium | 105.7 | drug |
pantoprazole — | 323.510 | 81.3% | Nierenversagen im Endstadium | 61.2 | drug |
palbociclib — | 94.183 | 52.6% | Tumorprogression | 107.7 | drug |
pain reliever — | 247.094 | 87.3% | Infusionsbedingte Reaktion | 17.5 | drug |
paclitaxel (aibumin-bound) — | 79.282 | 96.9% | Knochenmarkhemmung | 29.6 | drug |
paclitaxel — | 95.870 | 96.3% | Knochenmarkhemmung | 25.6 | drug |
oxycodone hydrochloride and acetaminophen — | 97.801 | 82.1% | Abhängigkeit | 133.7 | drug |
oxycodone hydrochloride — | 281.587 | 86.9% | Abhängigkeit von Medikamenten | 194.1 | drug |
oxycodone — | 376.208 | 84.2% | Abhängigkeit von Medikamenten | 131.2 | drug |
oxaliplatin — | 71.867 | 97.0% | Neurotoxizität | 27.4 | drug |
ondansetron tablets — | 105.951 | 80.8% | Fieberhafte Neutropenie | 15.3 | drug |
ondansetron hydrochloride — | 118.451 | 79.6% | Fieberhafte Neutropenie | 14.2 | drug |
ondansetron — | 118.456 | 79.6% | Fieberhafte Neutropenie | 14.2 | drug |
onabotulinumtoxina — | 75.403 | 19.1% | Mehrfachverwendung eines Einwegprodukts | 312.5 | drug |
omeprazole magnesium — | 438.661 | 72.0% | Nierenversagen im Endstadium | 65.4 | drug |
omeprazole — | 442.282 | 71.8% | Nierenversagen im Endstadium | 65.1 | drug |
omalizumab — | 82.197 | 53.2% | Atemwegsobstruktion | 50.7 | drug |
olanzapine — | 107.378 | 85.3% | Neuroleptisches malignes Syndrom | 57.7 | drug |
nivolumab — | 94.833 | 89.3% | Immunvermittelte Enterokolitis | 165.1 | drug |
natalizumab — | 180.199 | 31.2% | Allgemeines Symptom | 47.9 | drug |
naproxen sodium tablet — | 65.379 | 40.8% | Handfehlbildung | 55.0 | drug |
naproxen sodium — | 162.972 | 58.3% | Gelenkentzündung | 37.6 | drug |
naproxen — | 162.981 | 58.3% | Gelenkentzündung | 37.6 | drug |
mycophenolate mofetil hydrochloride — | 131.742 | 91.3% | Abstoßung der Transplantation | 171.7 | drug |
mycophenolate mofetil — | 131.745 | 91.3% | Abstoßung der Transplantation | 171.7 | drug |
morphine sulfate — | 119.783 | 85.6% | Abhängigkeit von Medikamenten | 59.6 | drug |
morphine — | 190.113 | 86.1% | Abhängigkeit von Medikamenten | 34.4 | drug |
montelukast sodium — | 118.894 | 60.7% | Atemwegsobstruktion | 48.4 | drug |
montelukast — | 171.338 | 62.5% | Asthma | 27.1 | drug |
mometasone — | 65.258 | 51.4% | Verwendung eines minderwertigen Geräts | 198.4 | drug |
mirtazapine — | 89.349 | 83.8% | Suizidversuch | 7.3 | drug |
minoxidil foam 5% (womens) — | 3.436.075 | 75.5% | Fieberhafte Neutropenie | 8.6 | drug |
metoprolol tartrate — | 268.317 | 70.6% | Vorhofflimmern | 6.5 | drug |
metoprolol succinate — | 83.951 | 63.0% | Vorhofflimmern | 5.5 | drug |
metoprolol — | 347.924 | 68.7% | Vorhofflimmern | 6.3 | drug |
metoclopramide hydrochloride — | 75.807 | 89.5% | Tardive Dyskinesie | 468.2 | drug |
metoclopramide — | 75.807 | 89.5% | Tardive Dyskinesie | 468.2 | drug |
methylprednisolone — | 167.055 | 88.8% | Infusionsbedingte Reaktion | 15.8 | drug |
methylphenidate — | 72.539 | 50.6% | Rötung an der Anwendungsstelle | 20.2 | drug |
methotrexate sodium — | 478.279 | 73.3% | Gelenkentzündung | 137.6 | drug |
methotrexate — | 484.893 | 72.6% | Gelenkentzündung | 135.8 | drug |
metformin hydrochloride — | 89.081 | 69.5% | Laktatazidose | 46.6 | drug |
metformin er 750 mg — | 294.217 | 67.9% | Laktatazidose | 47.4 | drug |
metformin er 500 mg — | 294.217 | 67.9% | Laktatazidose | 47.4 | drug |
metformin — | 433.187 | 66.8% | Laktatazidose | 75.1 | drug |
magnesium — | 813.618 | 70.5% | Nierenversagen im Endstadium | 49.6 | drug |
macitentan — | 67.863 | 71.2% | Pulmonale arterielle Hypertonie | 93.4 | drug |
losartan potassium — | 87.627 | 61.0% | Chronische Nierenerkrankung | 4.3 | drug |
losartan — | 206.980 | 63.8% | Chronische Nierenerkrankung | 6.6 | drug |
lorazepam — | 176.559 | 76.9% | Vollendeter Suizid | 5.3 | drug |
loratadine — | 113.035 | 44.8% | Zusätzliche Dosis verabreicht | 9.0 | drug |
lisinopril — | 310.213 | 61.0% | Angioödem | 12.7 | drug |
lidocaine — | 94.188 | 56.9% | Lippenherpes | 35.1 | drug |
levothyroxine sodium anhydrous — | 97.348 | 69.8% | Allgemeine Verschlechterung des körperlichen Zustands | 4.4 | drug |
levothyroxine sodium — | 308.680 | 60.2% | Herzklopfen | 3.7 | drug |
levonorgestrel — | 205.479 | 32.8% | Intrauterinpessar ausgestoßen | 11448.8 | drug |
levetiracetam oral — | 75.246 | 88.5% | Resistenz gegen mehrere Medikamente | 195.7 | drug |
levetiracetam injection — | 75.261 | 88.5% | Resistenz gegen mehrere Medikamente | 195.6 | drug |
levetiracetam in sodium chloride — | 75.245 | 88.5% | Resistenz gegen mehrere Medikamente | 195.7 | drug |
levetiracetam — | 130.496 | 82.8% | Resistenz gegen mehrere Medikamente | 146.4 | drug |
leuprolide acetate — | 76.176 | 45.8% | Fehler bei der Produktzubereitung | 981.6 | drug |
leuprolide — | 77.571 | 46.3% | Fehler bei der Produktzubereitung | 961.6 | drug |
lenalidomide — | 414.396 | 64.0% | Plasmozytom | 40.2 | drug |
leflunomide — | 102.951 | 82.4% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 1455.6 | drug |
lansoprazole — | 175.073 | 87.3% | Nierenversagen im Endstadium | 143.9 | drug |
lamotrigine extended-release — | 69.943 | 80.9% | Arzneimittelreaktion mit Eosinophilie und systemischen Symptomen (DRESS) | 22.5 | drug |
lamotrigine chewable dispersible — | 69.814 | 81.0% | Arzneimittelreaktion mit Eosinophilie und systemischen Symptomen (DRESS) | 22.6 | drug |
lamotrigine — | 129.256 | 71.8% | Stevens-Johnson-Syndrom | 21.5 | drug |
lamotirigine — | 69.812 | 81.0% | Arzneimittelreaktion mit Eosinophilie und systemischen Symptomen (DRESS) | 22.6 | drug |
iron — | 76.882 | 66.6% | Vermindertes Hämoglobin | 5.2 | drug |
interferon beta-1a — | 191.751 | 53.1% | Schub von Multipler Sklerose | 34.7 | drug |
insulin lispro — | 137.507 | 46.0% | Erhöhter Blutzucker | 54.5 | drug |
insulin glargine — | 243.678 | 51.6% | Erhöhter Blutzucker | 26.1 | drug |
insulin — | 492.190 | 55.0% | Erhöhter Blutzucker | 42.8 | drug |
infliximab — | 240.611 | 87.5% | Pemphigus | 228.2 | drug |
ibuprofen tablets usp, 200mg — | 195.040 | 72.9% | Chronische Nierenerkrankung | 6.6 | drug |
ibuprofen tablet, film coated — | 195.036 | 72.9% | Chronische Nierenerkrankung | 6.6 | drug |
ibuprofen oral — | 195.098 | 72.9% | Chronische Nierenerkrankung | 6.6 | drug |
ibuprofen capsules 200 mg — | 195.145 | 72.9% | Chronische Nierenerkrankung | 6.6 | drug |
ibuprofen capsule — | 198.873 | 72.2% | Chronische Nierenerkrankung | 6.5 | drug |
ibuprofen 200mg — | 195.216 | 72.9% | Infektion der unteren Atemwege | 10.3 | drug |
ibuprofen 200 mg — | 195.158 | 72.9% | Chronische Nierenerkrankung | 6.6 | drug |
ibuprofen — | 279.647 | 63.0% | Gelenkschwellung | 4.7 | drug |
ibupfrofen — | 195.038 | 72.9% | Chronische Nierenerkrankung | 6.6 | drug |
ibrutinib — | 79.578 | 77.5% | Vorhofflimmern | 11.3 | drug |
hydroxychloroquine sulfate — | 89.509 | 75.5% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 527.2 | drug |
hydroxychloroquine — | 149.345 | 78.0% | Pemphigus | 408.7 | drug |
hydromorphone hydrochloride — | 91.030 | 92.7% | Abhängigkeit von Medikamenten | 100.9 | drug |
hydrocortisone spray — | 65.082 | 83.2% | Herzbeutelentzündung | 43.5 | drug |
hydrocortisone lotion — | 65.091 | 83.2% | Herzbeutelentzündung | 43.5 | drug |
hydrocortisone cream — | 65.461 | 83.1% | Herzbeutelentzündung | 43.3 | drug |
hydrocortisone continuous spray — | 65.082 | 83.2% | Herzbeutelentzündung | 43.5 | drug |
hydrocortisone acetate — | 71.556 | 82.6% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 192.1 | drug |
hydrocortisone — | 121.305 | 79.3% | Gelenkentzündung | 50.7 | drug |
hydrocodone bitartrate — | 95.444 | 86.2% | Lernschwierigkeiten | 194.1 | drug |
hydrochlorothiazide — | 206.985 | 67.4% | Natriummangel im Blut | 7.2 | drug |
guaifenesin — | 199.480 | 55.5% | Infusionsbedingte Reaktion | 8.7 | drug |
golimumab — | 83.866 | 74.9% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 899.7 | drug |
gabapentin — | 359.779 | 63.3% | Medikament unwirksam für nicht zugelassene Indikation | 7.4 | drug |
furosemide — | 393.086 | 81.3% | Herzinsuffizienz mit Stauung | 9.3 | drug |
formoterol fumarate dihydrate — | 114.158 | 57.5% | Atemwegsobstruktion | 49.3 | drug |
formoterol fumarate — | 125.520 | 56.1% | Asthma | 27.1 | drug |
folic acid — | 246.828 | 74.1% | Pemphigus | 252.1 | drug |
fluticasone propionate and salmeterol — | 99.522 | 50.6% | Asthma | 23.2 | drug |
fluticasone propionate — | 189.078 | 49.1% | Asthma | 15.0 | drug |
fluticasone furoate — | 84.208 | 42.9% | Produktbeschwerde | 68.3 | drug |
fluoxetine hydrochloride — | 124.895 | 71.6% | Serotonin-Syndrom | 23.5 | drug |
fluoxetine — | 129.920 | 71.4% | Serotonin-Syndrom | 23.3 | drug |
fluorouracil — | 75.164 | 94.6% | Schleimhautentzündung | 20.9 | drug |
fluconazole — | 68.732 | 84.7% | Fieberhafte Neutropenie | 13.4 | drug |
fish oil — | 88.731 | 48.8% | Hitzewallung | 7.4 | drug |
fingolimod hcl — | 85.806 | 51.4% | Läsion im zentralen Nervensystem | 66.3 | drug |
fingolimod — | 86.447 | 51.5% | Läsion im zentralen Nervensystem | 66.3 | drug |
fentanyl — | 113.392 | 85.5% | Drogenmissbrauch | 35.4 | drug |
famotidine — | 115.334 | 63.6% | Nierenversagen im Endstadium | 22.8 | drug |
ezetimibe — | 87.701 | 64.4% | Rhabdomyolyse | 9.4 | drug |
evolocumab — | 157.026 | 15.6% | Gerät schwer zu bedienen | 166.1 | drug |
etoposide — | 73.031 | 97.2% | Fieberhafte Neutropenie | 41.4 | drug |
etonogestrel — | 69.168 | 34.4% | Schwangerschaft mit Verhütungsimplantat | 803.8 | drug |
etanercept — | 592.886 | 36.0% | Gelenkentzündung | 58.4 | drug |
estradiol — | 190.011 | 50.9% | Chronische Cholezystitis | 568.3 | drug |
esomeprazole magnesium — | 230.681 | 71.5% | Nierenversagen im Endstadium | 120.7 | drug |
esomeprazole — | 233.118 | 71.8% | Nierenversagen im Endstadium | 119.4 | drug |
escitalopram oxalate — | 70.619 | 78.0% | Serotonin-Syndrom | 24.3 | drug |
escitalopram — | 136.935 | 67.2% | Suizidversuch | 6.3 | drug |
ergocalciferol — | 374.035 | 58.6% | Nasennebenhöhlenentzündung | 4.5 | drug |
epinephrine — | 109.279 | 64.4% | Nasennebenhöhlenentzündung | 8.6 | drug |
emtricitabine — | 77.542 | 77.0% | Knochendemineralisierung | 1132.5 | drug |
empagliflozin — | 69.331 | 60.1% | Euglykäämische diabetische Ketoazidose | 382.2 | drug |
dupilumab — | 438.499 | 11.1% | Atopische Dermatitis | 512.8 | drug |
duloxetine hydrochloride — | 184.178 | 61.5% | Entzugssyndrom | 11.7 | drug |
duloxetine — | 184.186 | 61.5% | Entzugssyndrom | 11.7 | drug |
dulaglutide — | 86.770 | 25.6% | Versehentliche Unterdosierung | 47.3 | drug |
drs. hydrocortisone — | 65.082 | 83.2% | Herzbeutelentzündung | 43.5 | drug |
doxycycline hyclate — | 65.451 | 72.9% | Chronische Nierenerkrankung | 11.6 | drug |
doxycycline — | 67.914 | 72.4% | Chronische Nierenerkrankung | 11.4 | drug |
doxorubicin — | 93.235 | 94.9% | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | 272.9 | drug |
docetaxel anhydrous — | 66.020 | 78.1% | Haarerkrankung | 733.4 | drug |
docetaxel — | 66.046 | 78.1% | Haarerkrankung | 733.0 | drug |
diphenhydramine hydrochloride — | 169.045 | 70.1% | Infusionsbedingte Reaktion | 22.8 | drug |
diphenhydramine — | 195.250 | 68.0% | Infusionsbedingte Reaktion | 20.0 | drug |
dimethyl fumarate — | 122.025 | 33.2% | Hitzewallung | 39.7 | drug |
digoxin — | 70.807 | 82.8% | Finanzielle Probleme | 29.4 | drug |
diclofenac sodium — | 153.661 | 60.5% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 582.5 | drug |
diclofenac — | 162.477 | 59.7% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 586.8 | drug |
diazepam oral solution (concentrate) — | 87.168 | 85.0% | Drogenmissbrauch | 20.0 | drug |
diazepam oral — | 87.170 | 85.0% | Drogenmissbrauch | 20.0 | drug |
diazepam — | 119.417 | 81.0% | Drogenmissbrauch | 17.2 | drug |
dextrose monohydrate — | 110.136 | 75.1% | Bauchfellentzündung | 16.8 | drug |
dextrose — | 184.033 | 80.0% | Kaliummangel im Blut | 6.8 | drug |
dexamethasone 1.5 mg — | 286.480 | 84.5% | Plasmozytom | 42.3 | drug |
dexamethasone — | 303.290 | 84.2% | Plasmozytom | 40.7 | drug |
denosumab — | 198.114 | 53.8% | Kieferknochennekrose | 57.0 | drug |
dalfampridine — | 71.172 | 28.2% | Therapieabbruch | 30.3 | drug |
dabigatran etexilate mesylate — | 72.043 | 76.4% | Hämorrhagische Anämie | 112.9 | drug |
dabigatran etexilate — | 78.131 | 77.5% | Hämorrhagische Anämie | 105.3 | drug |
cyclosporine — | 112.236 | 66.1% | Graft-versus-Host-Erkrankung | 58.0 | drug |
cyclophosphamide injection, solution — | 172.252 | 96.2% | Fieberhafte Neutropenie | 36.3 | drug |
cyclophosphamide for injection — | 172.253 | 96.2% | Fieberhafte Neutropenie | 36.3 | drug |
cyclophosphamide — | 172.254 | 96.2% | Fieberhafte Neutropenie | 36.3 | drug |
cool relief gel with aloe — | 65.082 | 83.2% | Herzbeutelentzündung | 43.5 | drug |
conjugated estrogens — | 69.274 | 70.2% | Östrogenrezeptor-Test positiv | 613.1 | drug |
clozapine — | 123.200 | 94.7% | Abnormales Differentialblutbild | 1445.8 | drug |
clopidogrel bisulfate — | 99.959 | 86.6% | Schwarzer Stuhl | 15.8 | drug |
clopidogrel — | 208.698 | 81.8% | Akuter Herzinfarkt | 12.5 | drug |
clonazepam — | 157.182 | 68.1% | Vollendeter Suizid | 8.5 | drug |
citalopram hydrobromide — | 105.394 | 82.2% | Vollendeter Suizid | 10.6 | drug |
citalopram — | 134.738 | 77.1% | Vollendeter Suizid | 8.6 | drug |
cisplatin — | 76.219 | 96.8% | Knochenmarkhemmung | 23.7 | drug |
ciprofolxacin — | 70.296 | 88.3% | Sehnenschmerzen | 82.9 | drug |
ciprofloxacin tablets — | 70.309 | 88.3% | Sehnenschmerzen | 83.0 | drug |
ciprofloxacin hydrochloride — | 95.796 | 83.3% | Sehnenschmerzen | 80.9 | drug |
ciprofloxacin — | 95.822 | 83.3% | Sehnenschmerzen | 80.9 | drug |
cetirizine hydrochloride — | 162.357 | 54.7% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 458.0 | drug |
cetirizine — | 169.947 | 54.8% | Pemphigus | 296.5 | drug |
certolizumab pegol — | 114.573 | 64.7% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 774.8 | drug |
celecoxib — | 129.432 | 70.3% | Psoriasis-Arthropathie | 16.7 | drug |
carvedilol — | 135.202 | 69.2% | Herzinsuffizienz mit Stauung | 9.2 | drug |
carboplatin — | 122.601 | 95.2% | Knochenmarkhemmung | 21.4 | drug |
carbamazepine — | 66.038 | 85.9% | Epilepsie | 23.0 | drug |
capecitabine — | 90.023 | 82.2% | Hand-Fuß-Syndrom | 98.7 | drug |
calcium carbonate — | 72.323 | 77.2% | Chronische Nierenerkrankung | 24.8 | drug |
calcium — | 592.039 | 68.4% | Diabetes mellitus Typ 2 | 25.8 | drug |
bupropion hydrochloride — | 107.988 | 48.8% | Suizidgedanken | 6.0 | drug |
bupropion — | 149.152 | 54.9% | Vollendeter Suizid | 10.9 | drug |
buprenorphine — | 123.005 | 60.8% | Unzureichende Schmerzbehandlung | 96.6 | drug |
budesonide and formoterol fumarate dihydrate — | 95.176 | 60.7% | Atemwegsobstruktion | 47.6 | drug |
budesonide — | 160.438 | 60.5% | Asthma | 25.0 | drug |
bortezomib — | 87.537 | 83.8% | Wiederkehrendes Plasmozytom | 150.9 | drug |
bisoprolol fumarate — | 132.846 | 96.6% | Hyperkaliämie | 11.2 | drug |
bevacizumab — | 126.289 | 88.8% | Proteinurie | 33.4 | drug |
baclofen — | 87.263 | 66.0% | Muskelsteifheit | 77.5 | drug |
azathioprine — | 88.112 | 86.8% | Colitis ulcerosa | 15.5 | drug |
atorvastatin calcium, film coated — | 67.696 | 63.1% | Diabetes mellitus Typ 2 | 9.6 | drug |
atorvastatin calcium — | 243.012 | 65.1% | Diabetes mellitus Typ 2 | 45.0 | drug |
atenolol — | 133.343 | 70.3% | Bradykardie | 6.9 | drug |
aspirin 81 mg — | 502.540 | 71.7% | GI-Blutung | 7.1 | drug |
aspirin 325 mg — | 500.597 | 71.8% | GI-Blutung | 7.1 | drug |
aspirin — | 552.493 | 69.8% | GI-Blutung | 7.4 | drug |
aripiprazole — | 123.730 | 65.0% | Spielsucht | 549.0 | drug |
apremilast — | 144.030 | 23.2% | Psoriasis-Arthropathie | 38.3 | drug |
antipruritic (anti-itch) — | 65.082 | 83.2% | Herzbeutelentzündung | 43.5 | drug |
anti-pruritic — | 65.082 | 83.2% | Herzbeutelentzündung | 43.5 | drug |
anti-itch cream — | 65.099 | 83.2% | Herzbeutelentzündung | 43.5 | drug |
anti itch — | 65.115 | 83.2% | Herzbeutelentzündung | 43.5 | drug |
amoxicillin — | 99.955 | 79.4% | Nierenversagen im Endstadium | 18.2 | drug |
amlodipine besylate — | 166.351 | 69.5% | Chronische Nierenerkrankung | 5.8 | drug |
amlodipine — | 431.535 | 74.3% | Chronische Nierenerkrankung | 5.8 | drug |
ambrisentan — | 123.381 | 64.8% | Pulmonale arterielle Hypertonie | 51.4 | drug |
alprazolam — | 202.857 | 70.7% | Drogenmissbrauch | 16.4 | drug |
allopurinol — | 153.758 | 82.1% | Gicht | 19.6 | drug |
alendronate sodium — | 100.127 | 78.6% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 710.9 | drug |
albuterol sulfate — | 289.568 | 56.8% | Problem mit dem Verabreichungssystem des Geräts | 58.0 | drug |
albuterol — | 291.471 | 56.8% | Problem mit dem Verabreichungssystem des Geräts | 57.7 | drug |
adapalene — | 181.371 | 0.7% | Chemische Verätzung der Haut | 282.9 | drug |
adalimumab — | 715.350 | 51.4% | Verabreichtes Produkt mit Kontraindikation | 19.6 | drug |
acyclovir — | 112.882 | 72.5% | Plasmozytom | 13.3 | drug |
acetaminophen, guaifenesin, and phenylephrine hydrochloride — | 156.094 | 59.3% | Infusionsbedingte Reaktion | 10.8 | drug |
acetaminophen tablet extended release — | 246.995 | 87.3% | Infusionsbedingte Reaktion | 17.6 | drug |
acetaminophen 500mg — | 247.585 | 87.3% | Infusionsbedingte Reaktion | 17.6 | drug |
acetaminophen — | 668.254 | 71.2% | Abhängigkeit | 21.0 | drug |
abatacept — | 135.351 | 60.5% | Anti-zyklisch-citrullinierte Peptid-Antikörper positiv | 562.7 | drug |
(to deliver) avobenzone 3%, homosalate 5%, octisalate 10%, octocrylene 5% — | 4.919.809 | 65.6% | Wechselwirkung mit Medikamenten | 3.9 | drug |
(to deliver) avobenzone 3%, homosalate 10%,octisalate 5%, octocrylene 5% — | 5.064.083 | 63.8% | Wechselwirkung mit Medikamenten | 3.7 | drug |
(to deliver) avobenzone 2%, homosalate 8%, octisalate 4.5%, octocrylene 7% — | 5.091.938 | 65.8% | Wechselwirkung mit Medikamenten | 3.9 | drug |